KIR2DL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, the other two inhibitory receptors KIR2DL1 and KIR3DL1 surveyed were neither affected by the onset of CML nor by any of the TKIs (Figure 1).